Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors.
Malcikova J, Stalika E, Davis Z, Plevova K, Trbusek M, Mansouri L, Scarfò L, Baliakas P, Gardiner A, Sutton LA, Francova HS, Agathangelidis A, Anagnostopoulos A, Tracy I, Makris A, Smardova J, Ghia P, Belessi C, Gonzalez D, Rosenquist R, Oscier D, Pospisilova S, Stamatopoulos K. Malcikova J, et al. Br J Haematol. 2014 Aug;166(4):621-5. doi: 10.1111/bjh.12893. Epub 2014 Apr 12. Br J Haematol. 2014. PMID: 24725250 Free article. No abstract available.
Inactivation of p53 and amplification of MYCN gene in a terminal lymphoblastic relapse in a chronic lymphocytic leukemia patient.
Stano-Kozubik K, Malcikova J, Tichy B, Kotaskova J, Borsky M, Hrabcakova V, Francova H, Valaskova I, Bourkova L, Smardova J, Doubek M, Brychtova Y, Pospisilova S, Mayer J, Trbusek M. Stano-Kozubik K, et al. Among authors: malcikova j. Cancer Genet Cytogenet. 2009 Feb;189(1):53-8. doi: 10.1016/j.cancergencyto.2008.10.003. Cancer Genet Cytogenet. 2009. PMID: 19167613
Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage.
Malcikova J, Smardova J, Rocnova L, Tichy B, Kuglik P, Vranova V, Cejkova S, Svitakova M, Skuhrova Francova H, Brychtova Y, Doubek M, Brejcha M, Klabusay M, Mayer J, Pospisilova S, Trbusek M. Malcikova J, et al. Blood. 2009 Dec 17;114(26):5307-14. doi: 10.1182/blood-2009-07-234708. Epub 2009 Oct 22. Blood. 2009. PMID: 19850740 Free article.
High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.
Kotaskova J, Tichy B, Trbusek M, Francova HS, Kabathova J, Malcikova J, Doubek M, Brychtova Y, Mayer J, Pospisilova S. Kotaskova J, et al. Among authors: malcikova j. J Mol Diagn. 2010 May;12(3):328-34. doi: 10.2353/jmoldx.2010.090100. Epub 2010 Mar 12. J Mol Diagn. 2010. PMID: 20228263 Free PMC article.
Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia.
Trbusek M, Smardova J, Malcikova J, Sebejova L, Dobes P, Svitakova M, Vranova V, Mraz M, Francova HS, Doubek M, Brychtova Y, Kuglik P, Pospisilova S, Mayer J. Trbusek M, et al. Among authors: malcikova j. J Clin Oncol. 2011 Jul 1;29(19):2703-8. doi: 10.1200/JCO.2011.34.7872. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606432
Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia.
Doubek M, Trbušek M, Malčíková J, Brychtová Y, Smardová J, Lochmanová J, Panovská A, Skuhrová Francová H, Mráz M, Tichý B, Sebejová L, Navrkalová V, Plevová K, Kuglík P, Mayer J, Pospíšilová S. Doubek M, et al. Among authors: malcikova j. Leuk Lymphoma. 2012 Sep;53(9):1817-9. doi: 10.3109/10428194.2012.658794. Epub 2012 Mar 1. Leuk Lymphoma. 2012. PMID: 22263566 No abstract available.
The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.
Malcikova J, Razga F, Jurcek T, Dvorakova D, Zackova D, Toskova M, Sebejova L, Smardova J, Oltova A, Vankova G, Jurackova L, Trbusek M, Pospisilova S, Mayer J, Racil Z. Malcikova J, et al. Leuk Lymphoma. 2013 Sep;54(9):2083-7. doi: 10.3109/10428194.2012.762649. Epub 2013 Feb 1. Leuk Lymphoma. 2013. PMID: 23289360 No abstract available.
56 results